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Abstract
Background: The antimalarial drug Pyrimethamine has been suggested to exert an antitumor activity by inducing
apoptotic cell death in cancer cells, including metastatic melanoma cells. However, the dose of Pyrimethamine to
be considered as an anticancer agent appears to be significantly higher than the maximum dose used as an
antiprotozoal drug.
Methods: Hence, a series of Pyrimethamine analogs has been synthesized and screened for their apoptosis
induction in two cultured metastatic melanoma cell lines. One of these analogs, the Methylbenzoprim, was
further analyzed to evaluate cell-cycle and the mechanisms of cell death. The effects of Methylbenzoprim were
also analyzed in a severe combined immunodeficiency (SCID)-mouse xenotransplantation model.
Results: Low dose of Methylbenzoprim was capable of inducing cytotoxic activity and a potent growth-inhibitory
effect by arresting cell cycle in S-phase in melanoma cells. Methylbenzoprim was also detected as powerful
antineoplastic agents in SCID-mouse although used at very low dose and as a single agent.
Conclusions: Our screening approach led to the identification of a “low cost” newly synthesized drug
(methylbenzoprim), which is able to act as an antineoplastic agent in vitro and in vivo, inhibiting melanoma
tumor growth at very low concentrations.
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Background
Metastatic melanoma has a poor prognosis and fre-
quently develops resistance to standard therapies. Re-
cently, new treatment options have been evaluated in
the clinic and the results with immunotherapy and tar-
geted therapy were promising [1]. Nevertheless, the ini-
tial excitement about the possibility of having discovered
new effective approaches to treat melanoma has been
followed by a degree of discouragement because these
therapies are usually associated with high costs, side ef-
fects and none appears to be curative when used as a
single agent [2, 3]. Their efficacy may be enhanced in
combination with other chemotherapeutic agents [4, 5].
Actually, the drug dacarbazine, and its orally active
analogue temozolomide (TMZ) remain the gold stand-
ard in melanoma chemotherapy. However, the response
rate of melanoma to these drugs is approximately 20 %,
underscoring the need to develop more effective treat-
ments [6].
In this context, recent evidence has shown that antimal-
arial drugs could be beneficial in the treatment of different
types of tumors [7, 8]. Pyrimethamine (2,4-diamino-5-p-
chlorophenyl-6-ethyl-pyrimidine; Pyr) is already used in
humans as an orally administered drug for the treatment
of infections caused by protozoan parasites (e.g. malaria
and toxoplasma). Pyr belongs to the group of antifolate
drugs inhibiting dihydrofolate reductase (DHFR), an en-
zyme, which is essential for the synthesis of folic acid, a
cofactor for DNA synthesis [9]. DHFR inhibitors, e.g.
methotrexate, have been studied for many years as anti-
cancer agents since antifolates have greater selective tox-
icity toward rapidly dividing cells such as tumor cells.
Previous studies have also demonstrated that Pyr is a po-
tent pro-apoptotic inducer in cancer cells, e.g. in meta-
static melanoma cells [10, 11]. It has been suggested that
the mechanism underlying this activity involves both the
activation of the caspase cascade (e.g. caspases 8–9 and 3)
and cathepsin cascade (e.g. cathepsin B). A remarkable in-
hibition of cell growth and a S-phase cell cycle arrest was
also demonstrated.
Unfortunately, dose-related adverse effects of Pyr have
been described since its introduction in the clinical prac-
tice, including bone marrow suppression with leukopenia,
thrombocytopenia and megaloblastic anemia [12–15]. Al-
though, some experimental studies suggested that a dose
of 50 mg/day of Pyr could be well tolerated [16, 17], clin-
ical trials have also shown that unwanted effects are con-
nected to the individual variability of patients. On these
bases, Pyr should be used with caution in patients with
impaired immune system, heart diseases and reduced
renal or hepatic function. In regard to this, different stud-
ies have shown that the highest risks are found in individ-
uals treated with Pyr at or above 50 mg/day [15, 18–23].
According to the above described potential toxicity and
taking into consideration the therapeutic potential of Pyr,
as well as the demand for drug repositioning of low-cost
agents such as Pyr [24, 25], a series of Pyr derivatives has
been synthesized and screened for their activity on melan-
oma. We report here the results obtained in melanoma
cultured cells and in xenografted animals that point at one
of these Pyr-analogs, the MBP, as capable of hindering
metastatic melanoma tumor growth at concentrations 10-
folds lower than Pyr.
Methods
Cell lines
Human metastatic melanoma cell lines MeWo and
Mel501 were cultured in RPMI 1640 (Life Technolo-
gies, Invitrogen) supplemented with 10 % heat-
inactivated fetal bovine serum (Euroclone), 2 mmol/L
glutamine (Sigma-Aldrich, St. Louis, MO, USA) and
50 μg/mL gentamicin (Sigma). Tumor cells were
tested as Mycoplasma-free (Mycoplasma detection kit;
(Roche, Switzerland).
Synthesis of Pyrimethamine analogues
The target analogues were readily prepared from Pyri-
methamine (Pyr) [26, 27]. Briefly, direct nitration of Pyr
under standard condition afforded m-nitropyrimethamine
(MNP) in near quantitative yield. Reduction of MNP to
the corresponding amine, followed by diazotisation and
treatment with sodium azide, gave m-azidopyrimethamine
(MZP). Conversion to the ethanesulfonate salt (MZPES)
was achieved on treatment of MZP with aqueous ethane-
sulfonic acid. Methylbenzoprim (MBP) was synthesized
from MNP in high yield by displacement of the 4-chloro
substituent with N-benzylmethylamine employing 2-
ethoxyethanol as solvent. Iso-Pyrimethamine (Iso-Pyr)
was synthesised by following the method of Russell and
Hitchings [28]. Structural features of Pyr-analogs are
shown in (Fig. 1).
Chemicals and drugs
Pyr (Sigma), Pyr-analogues indicated above and TMZ
(Sigma) were dissolved in DMSO (no precipitation of
drug was observed on addition of the DMSO solution to
aqueous medium); Leucovorin (Sigma) and Chloroquine
(CQ) (Sigma) were dissolved in water and were diluted
in RPMI 1640 immediately before experiments. The ca-
thepsin B inhibitor CA-074-Me (Calbiochem, Millipore,
Germany) and pan-caspase inhibitor z-VAD-fmk (R&D
System, USA) were diluted in RPMI 1640 immediately
before experiments.
Treatments
Melanoma cells were exposed to Pyr (8 μg/ml), TMZ
(100 μmol/L), Pyr-analogues (0.8, 8, 80 μg/ml) for 24, 48
and 72 h. In the combined treatments, Leucovorin (LV)
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(10 μg/ml) was given at the same time points of the
above drugs; CQ (10 μM) was given 16 h before the
treatment with Pyr or MBP; the cathepsin B inhibitor
(CA-074-Me, 10 μmol/L) and the pan-caspase inhibitor
z-VAD-fmk (50 μmol/L) were added to the culture
medium 2 h before the treatment.
Cell viability assay
CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega, Madison, WI) was used to determine
cytotoxic effects resulting from treatment with drugs.
Melanoma cells were plated at a density of 3 × 103 cells/
well in 96-well plates, and then treated with various con-
centrations of MBP and Pyr for 24, 48, and 72 h. At the
end of the treatment period, 20 μl of 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium (MTS) reagent were added to each
well. The plates were incubated for 30 min at 37 °C in
the dark. Absorbance at 450 nm was determined on
Opsys MR spectrophotometer (DYNEX Technologies,
Denkendorf, Germany) using Windows Revelation
QuickLink software. Each experimental condition was
performed in triplicate and repeated at least twice. All
values were normalized with respect to the viability of
untreated cells.
Cell death evaluation
Quantitative evaluation of apoptosis was performed by a
double staining flow cytometry method using FITC-
conjugated Annexin V (AV)/propidium iodide (PI) apop-
tosis detection kit (Marine Biological Laboratory, MBL,
USA) according to the manufacturer’s protocol. Reported
data refer to both early (AV+/PI− cells, still alive) and late
(AV+/PI+ cells, dead cells) apoptotic melanoma cells.
Western blotting analysis
Cell lines were lysed in RIPA buffer (100 mM Tris–HCL
pH 8, 150 mM NaCl, 1 % Triton X-100, 1 mM MgCl,
25 mM NaVO4) in the presence of complete protease-
inhibitor mixture (Sigma). Immunoblotting was per-
formed with antibodies to: caspase-9 (rabbit polyclonal
antibody, Enzo Life Sciences); caspase-8 (mouse mono-
clonal antibody, Transduction Laboratories); caspase-3
(mouse monoclonal antibody, Enzo Life Sciences); ca-
thepsin B (rabbit polyclonal antibody, Calbiochem). As a
control, the membranes were incubated with specific
antibodies of anti-α-tubulin (mouse monoclonal anti-
body, Sigma). The intensities of bands of active frag-
ments were quantified normalizing to Tubulin. The
optical density of the bands [integrated area in arbitrary
units (AU)] was measured by using the National Insti-
tutes of Health Image J software (rsb.info.nih.gov/ij).
Fig. 1 Chemical structures. Structures of Pyrimethamine (Pyr), Iso-Pyrimethamine (Iso-Pyr), m-Nitropyrimethamine (MNP), Methylbenzoprim (MBP)
and m-Azidopyrimethamine ethanesulfonate salt (MZPES). Structural differences in Pyrimethamine analogues are highlighted by boxes
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Cathepsin B
Anti-cathepsin B polyclonal antibody (Calbiochem) was
used to evaluate the expression of activated cathepsin B
by flow cytometry analysis. Control and treated cells
were fixed with 4 % paraformaldehyde in phosphate-
buffered saline (PBS) for 30 min at room temperature.
After washing in the same buffer, cells were perme-
abilized with 0.5 Triton X-100 (Sigma) in PBS for 5 min.
Then cells were incubated with Anti-cathepsin B poly-
clonal antibody (Calbiochem) and after 30 min at 37 °C,
cells were washed and then incubated with anti-rabbit
fluorescein-linked whole antibodies (Molecular Probes,
Eugene, OR, USA).
Caspase activity
Caspase-9, caspase-8 and caspase-3 activities were
assayed by using the CaspGLOW fluorescein active cas-
pase staining kit (MBL), following the manufacturer’s in-
struction, as previously described [18]. Western blot was
performed as described above.
Cell cycle analysis
Cultured cells were treated with 1 mmol/L bromodeox-
yuridine (BrdU; BD Immunocytometry Systems) for
30 min, removed from culture and fixed in 70 % ice-cold
ethanol. 1 × 106 fixed cells were incubated in 3 N HCl
for 20 min. After washing with 0.1 mol/L Na2B4O7
(pH 8.5) to stop acid denaturation, cells were washed
twice with 1 % bovine serum albumin and 0.5 % Tween
20 and labeled with an anti-BrdU FITC-conjugated (BD
Immunocytometry Systems) for 30 min at 4 °C. Cells
were then stained with 40 μg/mL PI (Sigma) in the pres-
ence of 10 μmol/L RNase (Sigma) for 30 min at 37 °C
followed by analysis on a flow cytometer.
Analysis of autophagy
Detection of autophagy was performed by using Cyto-ID
Autophagy Detection Kit (Enzo Life Sciences, Lausen
Switzerland). The kit was optimized for detection of au-
tophagy in live cells by flow cytometry. CYTO-ID® Au-
tophagy Detection Kit measures autophagic vacuoles
and monitors autophagic flux in lysosomally inhibited
live cells using a dye that selectively labels accumulated
autophagic vacuoles [29]. The probe is a cationic amphi-
philic tracer (CAT) dye that rapidly partitions into cells
in a similar manner as drugs that induce phospholipido-
sis. Careful selection of titratable functional moieties on
the dye prevents its accumulation within lysosomes, but
enables labeling of vacuoles associated with the autoph-
agy pathway. Induction of autophagic flux can be visual-
ized by enhanced accumulation of autophagic vesicles if
lysosomal function is inhibited, preventing removal of
these vesicles.
This assay provides a rapid, specific and quantitative
approach for monitoring autophagic activity at the cellu-
lar level by using a 488 nm-excitable probe that becomes
fluorescent in vesicles produced during autophagy.
Western blot was also performed, as described above.
Animals
CB.17 SCID/SCID female mice (Harlan Italy) were used
at 4 to 5 weeks of age and were kept under specific
pathogen-free conditions as previously described [11].
Before injection of Mycoplasma-free melanoma cells,
mice were weighed and divided into two control groups
(untreated and DMSO-treated) and two treatment
groups (Pyr and MBP) with eight mice per group. Mice
were injected s.c. into the right flank with 2 × 106 mel-
anoma Mel501 cells per mouse. Suspensions of Pyr
(45 mg/kg) were prepared daily in 5 % of DMSO in
aqueous methylcellulose solution and the suspensions
of MBP (12 mg/Kg) in 5 % of DMSO. At the onset of
tumor (i.e. 5 d from melanoma cell injection), mice
were given by oral gavage with the same volume
(200 μL) of vehicle or Pyr (45 mg/kg) or MBP (12 mg/
Kg) 5 d per week up to 40 d from injection (35 d of
drug administration). All mice were inspected daily and
the overall clinical condition was assessed. Tumor
growth was monitored by measuring maximal and
minimal diameters by caliper and tumor weight was
estimated with the formula: tumor weight (mg)
= [length(mm) × width2(mm)]/2. Procedures and facil-
ities followed the requirements of Commission Direct-
ive 86/609/EEC concerning the protection of animals
used for experimental and other scientific purposes.
Italian legislation is defined in D.L. no. 116 of January
27, 1992.
Histological analysis
Livers were formalin-fixed and paraffin embedded. Con-
secutive sections (5–6 μm thick) were stained with
hematoxylin-eosin and observed under a light micro-
scope (Olympus Corporation of the Americas, Center
Valley, USA).
Statistical analyses
All samples were analyzed with a FACSCalibur cytometer
(BD, Biosciences, Heidelberg, Germany) equipped with
a 488 argon laser. At least 20,000 events were acquired.
Data were recorded by a Macintosh computer using
CellQuestPro Software (BD). Statistical analyses were
performed by using Student’s t-test for paired samples
or non-parametric Anova test. All data reported were
verified in at least three different experiments and re-
ported as mean ± S.D. P-values < 0.05 were considered
as statistically significant.
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Results
Pyrimethamine analogues induce apoptosis in human
melanoma cell lines
It has already been shown that Pyr is a potent apoptosis
inducer in cancer cells [8–11, 17]. Thus, we first evalu-
ated the apoptosis-inducing potential of Pyr-analogues
in two human metastatic melanoma cell lines (MeWo
and Mel501) by using annexin V/propidium iodide (AV/
PI) double staining assay. Parallel analyses were carried
out in cells treated with Pyr and the chemotherapeutic
agent TMZ at a clinically relevant concentration
(100 μmol/L) [30]. We tested Pyr-analogues using the
same dosage of Pyr (8 μg/ml), which is known to induce
cell death in melanoma cells [10, 11] at different time
points, i.e. after 24, 48 and 72 h of treatment. In
addition, lower and higher doses (10-fold lower or
higher) were also evaluated. In Fig. 2, we reported the
percentage of annexin V-positive cells (apoptotic cells)
detected in the two cell lines. All screened compounds
were able to induce apoptosis, but only one of these was
more potent than Pyr and TMZ. In particular, the com-
pound MBP was able to induce apoptosis even at 10-
Fig. 2 Proapoptotic effects of Pyr-analogues versus Pyrimethamine and temozolomide on Mel501 and MeWo cell lines. Flow cytometric analysis
of apoptosis after the treatment with Pyr (8 μg/ml), TMZ (100 μmol/L) and Pyr-analogues (0.8, 8, 80 μg/ml) for 24, 48 and 72 h on Mel501 (left
panels) and MeWo (right panels) cell lines. Columns, mean values of 10 independent experiments; bars, SD. *, P < 0.05; **, P < 0.01, *** P < 0.001
significance compared with untreated cells. All screened compounds, Iso-Pyr (a), MNP (b), MZPES (c) and MBP (d), were able to induce apoptosis
but only one of these, MBP (d), was more potent than Pyr and TMZ even at very low concentration (0.8 μg/ml) in both cell lines. Note the significant
difference between MBP-treated and TMZ-treated samples after 48 and 72 h even at lower concentration of MBP (0.8 μg/ml)
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fold lower concentration (0.8 μg/ml) in both cell lines
(Fig. 2d, left and right panels). Of note, for all tested
concentrations, the percentage of necrotic cells (AV-/ PI
+ cells) was below 4 % with the exception of the higher
dose of MBP (80 μg/ml), which induced high levels of PI
single positive cells (necrotic cells) in both cell lines at
all time points tested (Table 1). On the basis of the
screening reported above, the MBP compound was se-
lected for further, more detailed analyses using the 0.8
and 8 μg/ml doses.
MTS cell viability assay and determination of the IC50 of
Methylbenzoprim
Since the newly synthesized compound MBP appears to
be effective at lower doses than Pyr, we evaluated it in
vitro IC50 value versus that of Pyr by MTS assay in both
Mel501 and MeWo cell lines. Treatment of the two hu-
man melanoma cell lines was performed for 24, 48 and
72 h at concentrations ranging between 0.8 and 64 μg/ml.
As shown in Fig. 3, a significant higher suppression of cell
growth by MBP versus Pyr was observed in both types of
Table 1 Single-color staining with Propidium iodide
Mel501 Ctr Pyr Temozolomide MBP 0.8ug/ml MBP 8ug/ml MBP 80ug/ml
24 h 0.4 1 0.1 0.6 2 11.5
48 h 1.2 4 4 2 3.6 14
72 h 1 3.6 3 2.4 4.2 25
MeWo Ctr Pyr Temozolomide MBP 0.8ug/ml MBP 8ug/ml MBP 80ug/ml
24 h 0.5 1 0.8 0.9 0.9 9.5
48 h 0.8 0.5 1 1.6 1.4 15
72 h 1 0.7 0,8 1 1 18
Numbers in the columns represent the average percentage of AV negative/PI positive (necrotic cells) obtained by 10 different experiments
Fig. 3 Antiproliferative effects of Methylbenzoprim and Pyrimethamine on Mel501 and MeWo cell lines. Viability of drug-treated Mel501 (left) and
MeWo (right) cell lines was evaluated at 24, 48 and 72 h by MTS assay. Each value is normalized to untreated cells. Data are the means ± S.D. of
three independent experiments bars, SD. *, P < 0.05; **, P < 0.01, *** P < 0.001 significance compared with untreated cells. We observed a time-
and dose-dependent decrease of cell proliferation in Pyr and MBP treated cells, but at different doses (from 0.8 to 64 μg/ml). In particular, after
72 h of exposure Mel501 showed an IC50 of 0.8 μg/ml for MBP, indicating a much higher activity of this agent with respect to Pyr, characterized
by an IC50 ranging between 16 and 32 μg/ml. Similarly, MeWo cells resulted in much more susceptibility to the antiproliferative effects of MBP,
since the IC50 of this agent ranged between 4 and 8 μg/ml as compared with that of Pyr (32–64 μg/ml)
Tommasino et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:137 Page 6 of 18
cancer cells. Although for both drugs we observed a time
and dose-dependent inhibition of cell proliferation, this
event occurred earlier and at lower doses when cells were
treated with MBP. In particular, MBP showed higher cyto-
toxic potential against Mel501 cells with IC50 = 0.8 μg/ml
after 72 h of exposure, with respect to Pyr, characterized
by IC50 ranging between 16 and 32 μg/ml. Similarly,
MeWo cells resulted in much more susceptibility to the
anti-proliferative effects of MBP, since, after 72 h, the IC50
of this agent ranged between 4 and 8 μg/ml as compared
with that of Pyr (32–64 μg/ml).
Methylbenzoprim induces cathepsin B and caspase
dependent apoptosis on melanoma cells
In previous studies we showed Pyr induced apoptosis in
melanoma cells via a mechanism that brought into play
both the caspase and cathepsin cascades [11]. To iden-
tify the apoptotic pathway being activated in response to
Fig. 4 Pan-caspase inhibitor Z-VAD-FMK and the cathepsin B inhibitor CA-074-Me inhibit Methylbenzoprim-induced apoptosis in melanoma cells.
The percentage of apoptotic cells was evaluated after 24, 48 and 72 h of MBP (0.8, 8 μg/ml), the positive control Pyr (8 μg/ml) and untreated cells
in Mel501 (panel a) and MeWo (panel b) cell lines pretreated for 2 h with the pan-caspase inhibitor Z-VAD-FMK (50 μmol/L) or the cathepsin B
inhibitor CA-074-Me (10 μmol/L) or both. Columns, mean values of three independent experiments; bars, SD. *, P < 0.05; **, P < 0.01, *** P < 0.001
significance compared with Pyr and MBP treated cells. Z-VAD-FMK induced a protective effect in a time dependent manner in Mel501 and
MeWo cell lines (panels a and b, respectively). When cathepsin B inhibitor CA-074-Me was used, apoptosis was significantly abrogated after 24 h
treatment; this effect persisted after 48 h, while it was less evident after 72 h. Z-VAD-FMK and CA-074-Me, administered simultaneously, increased
protective effect in both cell lines at all time points analyzed (panels a and b)
Tommasino et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:137 Page 7 of 18
Fig. 5 (See legend on next page.)
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MBP (the caspase, the cathepsin pathway or both),
Mel501 and MeWo cell lines were initially pre-treated
with: i) the pan-caspase inhibitor Z-VAD-FMK and ii)
the cathepsin B inhibitor CA-074-Me, at different time
points (Fig. 4a and b). Consistent with our previous
study [11], pan-caspase (z-VAD-fmk) and cathepsin B
(CA-074-Me) inhibitors exerted protective effects at all
time points studied in both Mel501 (Fig. 4a) and MeWo
(Fig. 4b) cell lines. In particular, z-VAD-fmk induced a
protective effect in a time-dependent manner in both
cell lines (Fig. 4a and b). Interestingly, the observed ef-
fects were equally powerful at both low and high dosages
of MBP (0.8, 8 μg/ml). Similarly, when cathepsin B in-
hibitor CA-074-Me was used (Fig. 4a and b), apoptosis
was significantly abrogated after 24 h of treatment and
this effect persisted after 48 h but was less evident after
72 h. When caspase and cathepsin B inhibitors were ad-
ministered simultaneously, cell death appeared much
more inhibited in both cell lines at all time points ana-
lyzed (Fig. 4a and b).
In consideration of overlapping results in the two
tested melanoma cell lines, hereafter only data obtained
with the Mel501 cell line will be reported. The experi-
ments that follow were performed by comparing the
effects induced by both dosages of MBP (0.8, 8 μg/ml)
with Pyr (8 μg/ml) (Fig. 5). Hence, in accord with apop-
tosis inhibition results reported above, we next examined
the possible involvement of caspases in the antitumor
effects of MBP by both flow cytometric (Fig. 5) and
Western blot analyses (Fig. 6): the upstream caspases
caspase-8, (mainly involved in receptor-mediated apop-
tosis) and caspase-9 (mainly involved in mitochondria-
mediated apoptosis): caspase-3 (an executioner caspase);
the lysosomal protease cathepsin B. The lower dose of
MBP (0.8 μg/ml) showed effects comparable to that of
Pyr at 8 μg/ml, whereas the higher dose of MBP (8 μg/ml)
did not induce more relevant effects. In particular, flow
cytometric data showed a significant increase of caspase-8
activity starting from 24 h, reaching a peak at 48 h and the
plateau at 72 h (Fig. 5a) whereas the activation of caspase-
9 and caspase-3 was detected after treatment for 48 and
72 h (Fig. 5b and c). The representative histograms have
been provided as Additional file 1: Figure S.1A and S.1B.
Flow cytometric data also showed a significant increase of
cathepsin B activity starting from 48 h, which persisted at
later time points (72 h) (Fig. 5d). The representative histo-
grams have been provided as Additional file 1: Figure S.2A
and S.2B. Western Blot (Fig. 6 left panels) and densitomet-
ric analysis (Fig. 6 right panels) confirmed these results by
showing an early activation of caspase 8, whereas caspase
9, caspase 3 and Cathepsin B activation occurred at later
time points.
Taken together, these experiments suggest that MBP
induces pro-apoptotic effects, mediated by both caspase-
and cathepsin-dependent pathways, at a significantly
lower dose than Pyr (0.8 μg/ml and 8 μg/ml, respectively).
Methylbenzoprim induces S-phase cell cycle arrest
To further investigate the effects induced by low dose of
MBP, Mel501 cell cultures were treated with MBP and
Pyr as described above and then analyzed for cell cycle
distribution. As shown in Fig. 7, both Pyr and MBP
hampered cell cycle progression by arresting the cells in
S-phase; a corresponding decrease of cells in the G1 and
G2-M phases was also observed. In particular, the low
dose of MBP was sufficient to induce a high proportion
of cells in S-phase as compared to Pyr (Fig. 7b). The
formation of a hypodiploid sub-G1 peak (indicative of
cell loss due to apoptosis) was also detected (Additional
file 1: Figure S2), confirming the data already evaluated
by AV/PI double staining assay (see Fig. 2).
Taken together, these data suggest that a low dose of
MBP is able to induce both cell cycle arrest and cell loss
due to apoptosis leading to marked antiproliferative
effects.
Dihydrofolate reductase activity
Pyr belongs to the group of antifolate drugs blocking the
enzyme dihydrofolate reductase (DHFR) that is essential
for the synthesis of folic acid, a cofactor required for DNA
synthesis. Previous studies reported that Pyr effects are
mainly mediated by its antifolate activity in melanoma cells
[10]. To investigate whether the antifolate activity of MBP
could contribute to its antiproliferative effects in melan-
oma cells, we tested the apoptosis-inducing potential of
MBP in the Mel501 cell line pre-treated with the reduced
form of folate Leucovorin (LV, N5-formyltetrahydrofolate),
a drug widely used to counteract the effects of antifolates
[31]. In these experiments, Mel501 cell lines were treated
with LV alone and in combination with Pyr (8 μg/ml) and
(See figure on previous page.)
Fig. 5 Flow cytometric analysis of apoptotic proteases. The activation of caspases 8, caspase 9, caspase 3 and cathepsin B were evaluated at 24,
48 and 72 h of Pyr (8 μg/ml) and MBP (0.8, 8 μg/ml) treatment on Mel501 cells. Both caspases (8, 9 and 3) and cathepsin B are involved in MBP
induced apoptosis. Flow cytometric data showed: i) a significant increase of caspase-8 activity starting from 24 h, reaching a peak at 48 and the
plateau at 72 h (a); ii) activation of caspase-9 and caspase-3 after 48 and 72 h treatment (b and c,); iii) a significant increase of expression cathepsin B
starting from 48 h, which persisted at later time points (72 h) (d), after MBP treatment (0.8 μg/ml). The higher dose of MBP (8 μg/ml) did not induce
more relevant effects on the above proteases. Columns, mean values of three independent experiments; bars, SD. *, P < 0.05; **, P < 0.01; significance
compared with untreated cells
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MBP (0.8 μg/ml), after which apoptotic cell death was
evaluated.
As shown in Fig. 8a, LV abrogated significantly apop-
tosis at all time points upon MBP treatment whereas
was only partly able to counteract the apoptotic effects
induced by Pyr. Since we showed that MBP increased
expression of caspases (Fig. 5) and folate deficiency has
been suggested to increase the expression of caspases
Fig. 6 Western Blot analysis of apoptotic proteases. Western Blot analysis confirmed the activation of apoptotic proteases in Mel501 cells treated
with Pyr (8 μg/ml) and MBP (0.8, 8 μg/ml). Note that procaspase-8 (57 kDa) is early cleaved into the intermediate forms p43 and p41 and finally
processed to the active p18 subunit (Fig. 5a, left panel), and procaspase 9 (47 kDa) is cleaved in 35 kDa subunit (Fig. 5b, left panel). The cleavage
of caspase 3 (17 kDa) (Fig. 5c, left panel) and Cathepsin B (25 kDa) (Fig. 5d, left panel) occurred at later time points. The intensities of bands of
active caspase fragments were quantified by densitometric analysis (Fig. 6 a-d right panels). The values were normalized to Tubulin and expressed
as arbitrary units (AU). Columns, mean of three independent experiments; bars, SD. *, P < 0.05; **, P < 0.01
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[32], we also analyzed the effects of LV on expression of
apoptotic proteases in melanoma cells treated with MBP
as compared to Pyr. Interestingly, the increased expres-
sion of caspase 8 (Fig. 8b), caspase 9 (Fig. 8c) and cas-
pase 3 (Fig. 8d) induced by both MBP and Pyr
treatments was significantly reduced in the presence of
LV (Fig. 8b and d). Likewise, LV administration also hin-
dered the S-phase cell cycle arrest induced by both MBP
and Pyr (Fig. 8e).
Taken together, these data suggest that the antifolate
activity could contribute, at least in part, to the antitu-
mor effects of low dose MBP on melanoma cells, i.e. cell
death triggering and cell cycle arrest.
Autophagy modulation after Pyrimethamine and
Methylbenzoprim treatment
Available chemotherapeutic agents generally act killing
cancer cells by apoptosis whereas drugs inducing au-
tophagy are emerging as able to activate a common
pathway of resistance to both standard chemotherapies
and novel approaches (e.g. immuno- and targeted ther-
apies) [32]. We have previously reported that autophagy
can be modulated by Pyr [33]. Thus, to further compare
the effects induced by Pyr and MBP, Mel501 cells were
treated with the two antifolate drugs as described above,
and then analyzed for autophagy induction. In order to
better evaluate the autophagic process, two different
assays were used in parallel. First, we used a cationic
amphiphilic dye that selectively labels autophagic vacu-
oles exhibiting bright fluorescence (autophagosome de-
tection by Cyto ID) (Fig. 9a and b) and then we analyzed
the LC3-II turn-over by western blot (Fig. 9c and d) The
experiments were also performed in the presence or
absence of the late autophagy inhibitor CQ, [34] which
can be used to examine the autophagic flux. Generally, if
autophagy is occurring, the amount of LC3-II as well as
autophagic vacuoles will be higher in the presence of the
inhibitor. As expected, Pyr alone as well as the com-
bined treatment Pyr/CQ led to an increase of autopha-
gosome detection (Fig. 9a and b) and LC3II expression
level (Fig. 9c and d). At variance, according to the data
reported above, when we treated melanoma cells with
CQ in combination with MBP, no significant effects were
found, i.e. no significant changes in autophagosome for-
mation as evaluated by Cyto ID detection kit (Fig. 9a
and b) or by evaluating LC3II by western blotting (Fig. 9c
and d). As autophagy and apoptosis are two stress-
responses that are closely interconnected and Pyr was
concomitantly able to induce both apoptosis and au-
tophagy, we have also evaluated Pyr-induced apoptosis
in the presence of CQ. Interestingly, the late autophagy
inhibitor CQ significantly enhanced Pyr-induced apop-
tosis (about 2-folds) (Fig. 9e). In Fig. 9f a representative
experiment is shown. Conversely, low dose of MBP
Fig. 7 Methylbenzoprim induces S-phase cell cycle arrest. Cell-cycle distribution was evaluated by flow cytometric analysis on Mel501 proliferating
cells treated with Pyr (8 μg/ml) and MBP (0.8, 8 μg/ml) for 24, 48 and 72 h. Pie charts show the distribution of cells in the different each phase of
the cell cycle: S-phase (dark grey), G2/M (white) and G0/G1 (grey), obtained from three independent experiments. In particular, the low dose of
MBP (0.8 μg/ml) was sufficient to induce a high percentage of cells in S-phase as compared to high dose of Pyr (8 μg/ml) at all time points analyzed.
The representative histograms have been provided as Additional file 1: Figure S.3
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induced a significant increase of apoptotic rate and no
effects were observed adding CQ (Fig. 9e and f).
Methylbenzoprim reduces melanoma growth in a SCID
mouse model
The in vivo efficacy of MBP was examined by measuring
the reduction of tumor growth in a human melanoma
xenograft in severe combined immunodeficiency (SCID)
mice. Mel501 melanoma cells were injected into the
right flank of SCID mice and at the onset of tumor
(when tumors had approximately reached 50 mm3), mice
were treated with Pyr (45 mg/kg) or MBP (12 mg/kg)
for 5 days per week up to 40 days from tumor injection
for a total 35 days of drug administration. For mice
treatments, the doses of Pyr used were selected on the
basis of the pharmacokinetic studies carried out in rats
Fig. 8 Methylbenzoprim is a potent dihydrofolate reductase inhibitor. Flow cytometric and cell cycle analyses on Mel501 treated with Pyr (8 μg/
ml), MBP (0.8 μg/ml) and LV (10 ug/ml) for 24, 48 and 72 h. Flow cytometric data showed: i) LV was only partly able to counteract apoptotic
effects induced by Pyr, whereas apoptosis was significantly abrogated at all time points of MBP treatment (a); ii) the increased expression of
caspase-8 (b), caspase-9 (c) and caspase-3 (d) in both treatments (MBP and Pyr) was significantly reduced in the presence of LV (b-d) Columns,
mean values of three independent experiments; bars, SD. *, P < 0.05; **, P < 0.01, *** P < 0.001 significance compared with Pyr and MBP treated
cells. Pie charts (e) show the distribution of cells in each phase of the cell cycle: S-phase (dark grey), G2/M (white) and G0/G1 (grey), obtained from
three independent experiments. In particular, LV administration hindered the S-phase cell cycle arrest induced by both Pyr and MBP (e)
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Fig. 9 (See legend on next page.)
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[35] and of our previous work performed in SCID mice
[11]. In that work, we have analyzed a wide range of Pyr
doses (from 3 to 60 mg/ Kg). On the basis of these stud-
ies the dose of 45 mg/Kg was considered here [36]. The
dose of 45 mg/kg/d corresponds to a plasma concentra-
tion of 240 μmol/L [37]. In this study, we have also per-
formed preliminary experiments on SCID mice utilizing
a range of doses of MBP from 6 to 45 mg/kg (data not
shown). The lowest dose of MBP, which showed antitu-
mor effects comparable to those of Pyr at the dose of
45 mg/Kg, was 12 mg/kg. Of note, the chosen dose of
MBP was about three times lower than that of Pyr. Un-
treated and vehicle treated mice (DMSO) were also in-
cluded as control groups. Tumor growth was monitored
by measuring maximal and minimal diameters by caliper
and by evaluating tumor weight, which was estimated as
reported elsewhere [11]. In Fig. 10a, the mean of tumor
volume at various times after melanoma cell injection is
reported. Although a significant reduction of tumor
growth (P < 0.05) was observed in Pyr treated mice with
respect to untreated mice, stronger antitumor effects
were obtained with MBP since melanoma grew signifi-
cantly slower as compared to both vehicle- and Pyr-
treatments (Fig. 10a and b). Therefore, MBP exhibits in
vivo robust antitumor effects as a lowest dose of this
drug than Pyr is sufficient to inhibit more strongly the
tumor growth of human melanoma xenograft.
Comparing In vivo effects of Methylbenzoprim and
Pyrimethamine
Tumor growth and treatment with drugs had no effect
on the vitality and behavioral responses of animals. No
weight loss was observed either during or at the end of
the experiment with both treatments. Sacrifice and
macroscopic observations of the organs excised from
mice at the end of experiments (heart, spleen, kidneys
and lungs) showed no macroscopic signs of toxicity in
both Pyr and MBP treated groups of mice. Nevertheless,
a partially greenish bowel was observed in Pyr-treated
mice suggesting a possible occurrence of a blocked bile
duct or liver disorders. In order to deepen this aspect,
we have further analyzed the liver histologic features of
Pyr-treated mice compared to MBP-treated and un-
treated mice (Fig. 10). As shown in the micrographs
(Fig. 10, bottom panels), the liver architecture of Pyr-
treated and MBP-treated mice was well preserved and
there was no evidence of hepatocyte necrosis or
apoptosis.
Discussion
Successful therapy of metastatic melanoma represents
one of the main challenges of chemotherapeutic inter-
vention in the field of cancer control. Although clinical
protocols including new biological approaches (e.g. tar-
geted agents, immunotherapy) gave some encouraging
results, their efficacy and durable responses remain lim-
ited and new evidence indicates their use in combination
with chemotherapy [2, 38]. Thus, the search for novel
agents capable of exerting anticancer activity appears to
be still mandatory. Of great interest, drug repositioning
has been growing in importance in the last few years as,
by passing much of the early cost and time needed to
bring a drug to market, provides a number of low-cost
non-cancer drugs for cancer treatment to be exploited
in novel anticancer strategies with high therapeutic po-
tential and low-toxicity [39], allowing also access to
cures for a higher population of patients. Among these
are antimalarials, a class of compounds that have been
proposed as anticancer agents thanks to their anti-
proliferative activity since 1953 [40]. The reappraisal of
one these drugs, Pyr, stems from the encouraging results
obtained in the treatment of melanoma and other tu-
mors [7, 8, 10, 11]. In addition, Pyr is already used in
humans as an orally administered drug for the treatment
of infections caused by protozoan parasites. Of note, Pyr
belongs to the group of antifolate drugs that blocks the
(See figure on previous page.)
Fig. 9 Autophagy modulation after Pyr and MBP treatment. Autophagy was evaluated utilizing two different assays: a cationic amphiphilic dye
that selectively labels autophagic vacuoles (Cyto ID autophagy detection kit) by flow cytometric analysis (Fig. 9a-b) and the expression of LC3I/II
by WB analysis (Fig. 9c-d). Mel501 melanoma cells were treated with Pyr (8 μg/ml), and MBP (0.8 μg/ml) for 48 h. The experiments were
performed in the presence or absence of the late autophagy inhibitor CQ (10 μM) for an overnight treatment before the end of the experiment.
As shown by fluorescence histograms of Cyto-ID Green autophagy dye (Fig. 9a-b), Pyr treatment was able to induce a significant increase of
autophagic vacuoles. Note, the induction of autophagy can be better visualized when the removal of these vesicles is prevented by CQ.
Treatment with MBP did not induce significant autophagy and (as expected) CQ treatment (MBP/CQ) did not induce any significant effect.
Figure 9a, Columns, mean values of three independent experiments; bars, SD. *, P < 0.05; significance compared with untreated cells. #, P < 0.05;
##, P < 0.01; significance compared with CQ treated cells. In Fig. 9b the data of a representative experiment were shown. The data were confirmed
by western blot of LC3-II turn-over (Fig. 9d) in the presence or absence of CQ. The intensities of bands of LC3II were quantified by densitometric
analysis (Fig. 9c). The values were normalized to Tubulin and expressed as arbitrary units (AU). Columns, mean values of three independent
experiments; bars, SD. *, P < 0.05; significance compared with untreated cells. #, P < 0.05; ##, P < 0.01; significance compared with CQ treated cells.
As Pyr was able to induce both apoptosis and autophagy, we have also evaluated Pyr-induced apoptosis in the presence of CQ. As shown in
Fig. 9e, CQ significantly enhanced Pyr-induced apoptosis (about 2-fold) while MBP/CQ treatment did not induce any significant effect. Columns,
mean values of three independent experiments; bars, SD. *, P < 0.05; significance compared with untreated cells. #, P < 0.05; ##, P < 0.01; significance
compared with CQ treated cells. In Fig. 9f a representative experiment was shown
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enzyme dihydrofolate reductase (DHFR). DHFR inhibi-
tors have been studied for many years as anticancer
agents for their selective toxicity on rapidly dividing cells
such as tumor cells. With this in mind, a series of chem-
ically modified analogues of Pyr has been synthesized
and screened in the present work. Here, we report for
the first time that one of these, MBP, is a valuable candi-
date for drug repositioning for cancer treatment as it ex-
erts a powerful effect in both in vitro and in vivo on
metastatic melanoma via a mechanism partly overlaying
that of Pyr. In particular, multiple effects have been de-
tected: i) apoptosis triggering; ii) activation of cysteine
Fig. 10 Methylbenzoprim reduces melanoma growth in a SCID mouse model. Tumor growth features in SCID mice inoculated with the human
melanoma cell line Mel501 and treated with vehicle alone or Pyr or MBP by oral gavage. Pyr (45 mg/kg/day) and MBP (12 mg/kg/day) treatments
were started at the onset of the metastatic tumor (i.e. 5 d after melanoma cell injection). The dose of Pyr used to treat mice was chosen on the
basis of previous in vivo studies [11, 24] whereas the dose of MBP was chosen considering both the results of in vitro and preliminary in vivo
experiments. In (a) the mean tumor volume ± SD at different times after melanoma cell injection is reported. Note the significant values detected
in comparison with animals treated with vehicle alone (*) = P < 0.05; (**) = P < 0.01. b Upper panels. Micrographs show the difference of tumor size
between Pyr and MBP, compared with vehicle alone, when mice were sacrificed. Note, in particular, the significant reduction of tumor size
observed with MBP compared vehicle alone. Bottom panels. Liver histologic features of mice treated with vehicle (left), Pyr (middle) and MBP
(right). The liver architecture is well preserved. There is no evidence of hepatocyte necrosis or apoptosis, as compared to the control. Staining
with Hematoxylin eosin, original magnification 20×
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protease, e.g. cathepsin B, activity; iii) inhibition of cell
cycle progression, and iv) inhibition of DHFR activity.
Of note, MBP activity results associated with the activa-
tion of caspase cascade, as either apical caspase (caspase
8–9) or executioner caspase-3 and with the activity of
cathepsin B. Interestingly, this lysosomal cysteine prote-
ase has been hypothesized for many years as a further
actor in the cell death program execution [41–43].
Concerning the cell cycle, the blocking of S-phase and
its progression clearly represent an important cytostatic
activity of MBP, as for other anticancer drugs [44]. This
property could be of great relevance to develop powerful
antitumor combination treatments with drugs able to
affect cancer cells in S-phase, such as 5-fluorouracil [45].
In this regard, the inhibition of DHFR, probably at the
basis of the block in S-phase, could be of relevance since
folates are key determinants of cell proliferation and
represent essential targets for the control of cancer cell
growth, as it appears for the prototypical DHFR inhibitor
methotrexate, which nevertheless is endowed with high
toxicity [9]. Most importantly, the dose needed for
significant in vivo anticancer activity of MBP appears to
be about 5-fold lower than that of Pyr, suggesting that
lower doses of MBP could show adequate efficacy and
cause minor adverse effects compared to the group of
antifolate drugs already in use, such as Pyr and, mainly,
methotrexate.
A further key point to be considered in anticancer
treatments concerns the shift between cell death and cell
survival, sustained by apoptosis and autophagy, respect-
ively. Although the role of autophagy in cancer cells is
still controversial, recent studies have established that
autophagy can be activated to promote the survival of
tumor cells when these are exposed to cellular stress
conditions such as, radiation, chemotherapy or targeted
agents [46]. Autophagy is thus one of the mechanisms
that cancer cells have developed to evade therapy-
induced cell death. Apoptosis and autophagy are closely
intertwined processes and the shift apoptosis/autophagy
is extremely delicate and highly dependent on metabolic
interactions [33]. Previously, we reported that Pyr (as
TMZ and other chemotherapeutic drugs) is able to in-
duce autophagy at the early stage of treatment of tumor
cells [33, 47, 48]. In this context, the Food and Drug Ad-
ministration (FDA) have currently approved the use of
CQ in combination with conventional therapies to
counteract the mechanisms of cell survival in cancer
treatment (source http://www.fda.gov). Therefore, based
primarily on the ability to inhibit autophagy, CQ and its
derivative, hydroxychloroquine, are currently being in-
vestigated as adjuvant therapy in multiple clinical trials
for cancer treatment [47], leading to their use as poten-
tial chemotherapy and radiotherapy sensitizers rather
than antineoplastic. In agreement with these findings,
when we combined CQ with Pyr, we found an enhanced
cytotoxic effect and block of the autophagic flux. In con-
trast, in our experiments, MBP did not significantly in-
crease autophagy in comparison with baseline levels
found in control samples and its combination with CQ
did not modify the apoptotic rate of treated cancer cells.
Altogether, our data suggest that Pyr could promotes a
limited efficacy in vivo, due to its double-edged activity,
which induces both apoptotic cell death and autophagy,
therefore, limiting its antitumor activity. Conversely,
MBP exerts its strong antitumor activity, probably, by
stimulating pro-apoptotic effects only [33]. In addition,
as already proposed for antimalarial drug Pyr, the strong
efficacy of MBP at very low concentrations suggests that
the repositioning of these “low-cost drugs” in cancer
chemotherapy could be beneficial.
In a near future, the evaluation of the in vitro and in
vivo effects of MBP in combination with new melanoma
treatment options appears as mandatory. In particular,
further understanding of how MBP could interact with
immunotherapy and targeted therapy could present an op-
portunity for treatment of human metastatic melanoma.
Conclusion
Recent evidence has shown that antimalarial drugs could
be beneficial in the treatment of different types of tu-
mors. Among these the DHFR inhibitor Pyrimethamine
(Pyr) is a potent pro-apoptotic inducer in cancer cells.
Unfortunately, some dose-related adverse effects have
been described since Pyr introduction in clinical practice
and this weakened the enthusiasm for its anti-cancer
activity.
The results of this study led to the identification of a
series of Pyrimethamine analogs that were screened for
their ability to induce apoptosis in cultured metastatic
melanoma cell lines. All screened compounds were able
to induce apoptosis, but only one of these was more po-
tent than Pyr. In particular, the compound Methylbenzo-
prim (MBP) was able to act as an antineoplastic agent in
vitro and in vivo, inhibiting melanoma tumor growth at
very low concentrations. Our results suggest that MBP
could be considered as a novel agent of interest in the
development of new therapeutic strategies against meta-
static melanoma.
Additional file
Additional file 1: Figure S.1A and S.1B. Figure S.1A. Representative
image of FACS analysis showing activation of caspase 8, 9 and 3 in
Mel501 melanoma cells treated with Pyr and MBP. Figure S.1B.
Representative images of FACS analysis showing activation of caspase 8,
9 and 3 in MeWo melanoma cells treated Pyr and MBP. Figure S.2A.
Representative image of FACS analysis showing activation of cathepsin B
in Mel501 melanoma cells treated with Pyr and MBP. Figure S.2B.
Representative images of FACS analysis showing activation of cathepsin B in
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MeWo melanoma cells treated with Pyr and MBP. Figure S.3 Representative
images of FACS showing cell cycle analysis on Mel501 melanoma cells
treated with Pyr and MBP. Note Pyr and MBP hampered cell cycle
progression by arresting the cells in S-phase; corresponding decreases of
cells in the G1 and G2-M phases were also observed. In particular, the low
dose of MBP was sufficient to induce a high proportion of S-phase cells, and
thereby S-phase arrest, as compared to high dose of Pyr. The formation of a
hypodiploid sub-G1 peak (indicative of cell loss due to apoptosis) was also
detected confirming the data already evaluated by AV/PI double staining
assay. (PPTX 241 kb)
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